JMI LABS IS NOW PART OF LEARN MORE

Antifungal susceptibilities of Candida, Cryptococcus neoformans and Aspergillus fumigatus from the Asia and Western Pacific region: data from the SENTRY antifungal surveillance program (2010-2012).

Antifungal susceptibilities of Candida, Cryptococcus neoformans and Aspergillus fumigatus from the Asia and Western Pacific region: data from the SENTRY antifungal surveillance program (2010-2012). by Pfaller MA, Messer SA, Jones RN and Castanheira M. published in J. Antibiot. (Tokyo) 2015; 68 (9): 556-561

Analysis of vancomycin susceptibility testing results for presumptive categorization of telavancin.

Analysis of vancomycin susceptibility testing results for presumptive categorization of telavancin. by Mendes RE, Farrell DJ, Flamm RK, Sader HS and Jones RN published in J. Clin. Microbiol. 2015; 53 (8): 2727-2730

Validation of Sensititre dry-form broth microdilution panels for susceptibility testing of ceftazidime-avibactam, a broad-spectrum-beta-lactamase inhibitor combination.

Validation of Sensititre dry-form broth microdilution panels for susceptibility testing of ceftazidime-avibactam, a broad-spectrum-beta-lactamase inhibitor combination. by Jones RN, Holliday NM and Krause KM published in Antimicrob. Agents Chemother. 2015; 59 (8): 5036-5039,

In vitro activity of dalbavancin against drug resistant Staphylococcus aureus from a global surveillance program.

In vitro activity of dalbavancin against drug resistant Staphylococcus aureus from a global surveillance program. by McCurdy SP, Jones RN, Mendes RE, Puttagunta S and Dunne MW published in Antimicrob. Agents Chemother. 2015; 59 (8): 5007-5009

Ceftazidime/avibactam tested against Gram-negative bacteria from intensive care unit (ICU) and non-ICU patients, including those with ventilator-associated pneumonia.

Ceftazidime/avibactam tested against Gram-negative bacteria from intensive care unit (ICU) and non-ICU patients, including those with ventilator-associated pneumonia. by Sader HS, Castanheira M, Flamm RK, Mendes RE, Farrell DJ and Jones RN. published in Int. J. Antimicrob. Agents. 2015; 46 (1): 53-59

Accuracy of the ThermoFisher Scientific (SensititreTM) dry-form broth microdilution MIC product when testing ceftaroline.

Accuracy of the ThermoFisher Scientific (SensititreTM) dry-form broth microdilution MIC product when testing ceftaroline. by Jones RN, Holliday NM and Critchley IA. published in Diagn. Microbiol. Infect. Dis. 2015; 81 (4): 280-282

Arbekacin activity against contemporary clinical bacteria isolated from patients hospitalized with pneumonia.

Arbekacin activity against contemporary clinical bacteria isolated from patients hospitalized with pneumonia. by Sader HS, Rhomberg PR, Farrell DJ and Jones RN published in Antimicrob. Agents. Chemother. 2015; 59 (6): 3263-3270

Responding to the challenge of untreatable gonorrhea: ETX0914, a first-in-class agent with a distinct mechanism-of-action against bacterial Type II topoisomerases.

Responding to the challenge of untreatable gonorrhea: ETX0914, a first-in-class agent with a distinct mechanism-of-action against bacterial Type II topoisomerases. by Basarab GS, Kern GH, McNulty J, Mueller JP, Lawrence K, Vishwanathan K, Alm RA, Barvian K, Doig P, Galullo V, Gardner H, Gowravaram M, Huband M, Kimzey A, Morningstar M, Kutschke A, Lahiri SD, Perros M, Singh R, Schuck VJ, Tommasi R, Walkup G and Newman JV published in Sci. Rep. 2015; 5: 11827

In vitro activity of RX-P873 against Enterobacteriaceae, Pseudomonas aeruginosa, and Acinetobacter baumannii.

In vitro activity of RX-P873 against Enterobacteriaceae, Pseudomonas aeruginosa, and Acinetobacter baumannii. by Flamm RK, Rhomberg PR, Jones RN and Farrell DJ published in Antimicrob. Agents Chemother. 2015; 59 (4): 2280-2285

Detection of a new cfr-like gene, cfr(B), in Enterococcus faecium recovered from human specimens in the United States: Report from The SENTRY Antimicrobial Surveillance Program.

Detection of a new cfr-like gene, cfr(B), in Enterococcus faecium recovered from human specimens in the United States: Report from The SENTRY Antimicrobial Surveillance Program. by Deshpande LM, Ashcraft DS, Kahn HP, Pankey G, Jones RN, Farrell DJ and Mendes RE published in Antimicrob. Agents. Chemother. 2015; 59 (10): 6256-6261,

Analysis of 5-year trends in daptomycin activity tested against Staphylococcus aureus and enterococci from European and US hospitals (2009-2013).

Analysis of 5-year trends in daptomycin activity tested against Staphylococcus aureus and enterococci from European and US hospitals (2009-2013). by Sader HS, Farrell DJ, Flamm RK and Jones RN published in J. Global. Antimicrob. Res. 2015; 3: 161-165

Telavancin activity when tested by a revised susceptibility testing method against uncommonly isolated Gram-positive pathogens responsible for documented infections in hospitals worldwide (2011-2013).

Telavancin activity when tested by a revised susceptibility testing method against uncommonly isolated Gram-positive pathogens responsible for documented infections in hospitals worldwide (2011-2013). by Mendes RE, Sader HS, Flamm RK, Farrell DJ and Jones RN published in J. Global Antimicrob. Res. 2015; 3 (1): 36-39

Activity of ceftaroline and comparator agents tested against Staphylococcus aureus from patients with bloodstream infections in US medical centres (2009–13).

Activity of ceftaroline and comparator agents tested against Staphylococcus aureus from patients with bloodstream infections in US medical centres (2009–13). by Sader HS, Farrell DJ, Flamm RK and Jones RN published in J. Antmicrob. Chemother. 2015; 70 (7): 2053-2056, 2015

Ceftazidime-avibactam activity when tested against ceftazidime-nonsusceptible Citrobacter spp., Enterobacter spp., Serratia marcescens, and Pseudomonas aeruginosa from Unites States medical centers (2011-2014).

Ceftazidime-avibactam activity when tested against ceftazidime-nonsusceptible Citrobacter spp., Enterobacter spp., Serratia marcescens, and Pseudomonas aeruginosa from Unites States medical centers (2011-2014). by Sader HS, Castanheira M, Farrell DJ, Flamm RK and Jones RN published in Diagn. Microbiol. Infect. Dis. 2015; 83 (4): 389-394

Differences in potency and categorical agreement between colistin and polymyxin B when testing 15,377 clinical strains collected worldwide.

Differences in potency and categorical agreement between colistin and polymyxin B when testing 15,377 clinical strains collected worldwide. by Sader HS, Rhomberg PR, Farrell DJ and Jones RN. published in Diagn. Microbiol. Infect. Dis. 2015; 83 (4): 379-381.

Initial broth microdilution quality control guidelines for Debio 1452, a FabI inhibitor antimicrobial agent.

Initial broth microdilution quality control guidelines for Debio 1452, a FabI inhibitor antimicrobial agent. by Ross JE, Flamm RK and Jones RN published in Antimicrob. Agents Chemother. 2015; 59 (11): 7151-7152

Telavancin activity tested against Gram-positive clinical isolates from European, Russian and Israeli hospitals (2011-2013) using a revised broth microdilution testing method: Redefining the baseline activity of telavancin.

Telavancin activity tested against Gram-positive clinical isolates from European, Russian and Israeli hospitals (2011-2013) using a revised broth microdilution testing method: Redefining the baseline activity of telavancin. by Mendes RE, Flamm RK, Farrell DJ, Sader HS and Jones RN published in J. Chemother. 2016; 28 (2): 83-88

Noninvasive Streptococcus pneumoniae serotypes recovered from hospitalized adult patients in the United States in 2009 to 2012.

Noninvasive Streptococcus pneumoniae serotypes recovered from hospitalized adult patients in the United States in 2009 to 2012. by Mendes RE, Hollingsworth RC, Costello A, Jones RN, Isturiz RE, Hewlett D, Jr. and Farrell DJ published in Antimicrob. Agents. Chemother. 2015; 59 (9): 5595-5601

Determination of disk diffusion and MIC quality control guidelines for solithromycin, a novel fluoroketolide antibacterial against Neisseria gonorrhoeae.

Determination of disk diffusion and MIC quality control guidelines for solithromycin, a novel fluoroketolide antibacterial against Neisseria gonorrhoeae. by Riedel S, Ross JE, Farrell DJ, Flamm RK and Jones RN published in J. Clin. Microbiol.: 2015; 53 (12): 3888-3890

Microbiological assessment of polymyxin B components tested alone and in combination.

Microbiological assessment of polymyxin B components tested alone and in combination. by Kassamali Z, Prince RA, Danziger LH, Rotschafer JC, Rhomberg PR and Jones RN published in Antimicrob. Agents. Chemother. 2015; 59 (12): 7823-7825

Genotypic characterization of methicillin-mesistant Staphylococcus aureus recovered at baseline from Phase 3 pneumonia clinical trials for ceftobiprole.

Genotypic characterization of methicillin-mesistant Staphylococcus aureus recovered at baseline from Phase 3 pneumonia clinical trials for ceftobiprole. by Mendes RE, Deshpande LM, Costello AJ, Farrell DJ, Jones RN and Flamm RK published in Microb. Drug Resist.: 2016; 22 (1): 53-58,

In vitro activity of AZD0914, a novel bacterial DNA gyrase/topoisomerase IV inhibitor, against clinically relevant Gram-positive and fastidious Gram-negative pathogens.

In vitro activity of AZD0914, a novel bacterial DNA gyrase/topoisomerase IV inhibitor, against clinically relevant Gram-positive and fastidious Gram-negative pathogens. by Biedenbach DJ, Huband MD, Hackel M, de Jonge BL, Sahm DF and Bradford PA published in Antimicrob. Agents. Chemother. 2015; 59 (10): 6053-6063

Activity of ceftaroline and comparator agents tested against Staphylococcus aureus from patients with bloodstream infections in US medical centres (2009–13).

Activity of ceftaroline and comparator agents tested against Staphylococcus aureus from patients with bloodstream infections in US medical centres (2009–13). by Sader HS, Farrell DJ, Flamm RK and Jones RN. published in J. Antmicrob. Chemother. 2015; 70 (7): 2053-2056,

Update on the linezolid in vitro activity through the Zyvox® Annual Appraisal of Potency and Spectrum Program (2013).

Update on the linezolid in vitro activity through the Zyvox® Annual Appraisal of Potency and Spectrum Program (2013). by Mendes RE, Hogan PA, Streit JM, Jones RN and Flamm RK published in Antimicrob. Agents Chemother. 2015; 59 (4): 2454-2457

In vitro antifungal susceptibilities of isolates of Candida spp. and Aspergillus spp. from China to nine systemically active antifungal agents: Data from the SENTRY antifungal surveillance program, 2010 through 2012.

In vitro antifungal susceptibilities of isolates of Candida spp. and Aspergillus spp. from China to nine systemically active antifungal agents: Data from the SENTRY antifungal surveillance program, 2010 through 2012. by Pfaller MA, Castanheira M, Messer SA and Jones RN published in Mycoses. 2015; 58 (4): 209-214

Molecular mechanisms of sulbactam antibacterial activity and resistance determinants in Acinetobacter baumannii.

Molecular mechanisms of sulbactam antibacterial activity and resistance determinants in Acinetobacter baumannii. by Penwell WA, Shapiro AB, Giacobbe RA, Gu RF, Gao N, Thresher J, McLaughlin RE, Huband M, DeJonge BL, Ehmann DE and Miller AA published in Antimicrob. Agents Chemother. 2015; 59 (3): 1680-1689

In vitro spectrum of pexiganan activity when tested against pathogens from diabetic foot infections and with selected resistance mechanisms.

In vitro spectrum of pexiganan activity when tested against pathogens from diabetic foot infections and with selected resistance mechanisms. by Flamm RK, Rhomberg PR, Simpson KM, Farrell DJ, Sader HS and Jones RN published in Antimicrob. Agents Chemother. 2015; 59 (3): 1751-1754

Validation of a commercial dry-form broth microdilution device (Sensititre®) for testing tedizolid, a new oxazolidinone.

Validation of a commercial dry-form broth microdilution device (Sensititre®) for testing tedizolid, a new oxazolidinone. by Jones RN, Holliday NM and Rhomberg PR published in J. Clin. Microbiol. 2015; 53 (2): 657-659

Telavancin in vitro activity against a USA collection of methicillin-resistant Staphylococcus aureus, including resistant subsets.

Telavancin in vitro activity against a USA collection of methicillin-resistant Staphylococcus aureus, including resistant subsets. by Mendes RE, Sader HS, Flamm RK, Farrell DJ and Jones RN published in Antimicrob. Agents Chemother. 2015; 59 (3): 1811-1814

Ceftazidime-avibactam activity tested against multidrug-resistant Pseudomonas aeruginosa isolated from United States Medical Centers (2012-2013).

Ceftazidime-avibactam activity tested against multidrug-resistant Pseudomonas aeruginosa isolated from United States Medical Centers (2012-2013). by Sader HS, Castanheira M, Mendes RE, Flamm RK, Farrell DJ and Jones RN. published in Antimicrob. Agents Chemother.. 2015; 59 (6): 3656-3659

Activity of oritavancin against Gram-positive clinical isolates responsible for documented skin and soft-tissue infections in European and US hospitals (2010-2013).

Activity of oritavancin against Gram-positive clinical isolates responsible for documented skin and soft-tissue infections in European and US hospitals (2010-2013). by Mendes RE, Farrell DJ, Sader HS, Flamm RK and Jones RN published in J. Antimicrob. Chemother. 2015; 70 (2): 498-504

Baseline activity of telavancin when tested against Gram-positive clinical isolates responsible for documented infections in USA hospitals (2011-2012) applying the revised susceptibility testing method.

Baseline activity of telavancin when tested against Gram-positive clinical isolates responsible for documented infections in USA hospitals (2011-2012) applying the revised susceptibility testing method. by Mendes RE, Farrell DJ, Sader HS, Flamm RK and Jones RN published in Antimicrob. Agents Chemother. 2015; 59 (1): 702-706

Characterization of the novel DNA gyrase inhibitor AZD0914: Low resistance potential and lack of cross-resistance in Neisseria gonorrhoeae.

Characterization of the novel DNA gyrase inhibitor AZD0914: Low resistance potential and lack of cross-resistance in Neisseria gonorrhoeae. by Alm RA, Lahiri SD, Kutschke A, Otterson LG, McLaughlin RE, Whiteaker JD, Lewis LA, Su X, Huband MD, Gardner H and Mueller JP published in Antimicrob. Agents Chemother. 2015; 59 (3): 1478-1486

In vitro antibacterial activity of AZD0914, a new spiropyrimidinetrione DNA gyrase/topoisomerase inhibitor with potent activity against gram-positive, fastidious gram-negative, and atypical bacteria.

In vitro antibacterial activity of AZD0914, a new spiropyrimidinetrione DNA gyrase/topoisomerase inhibitor with potent activity against gram-positive, fastidious gram-negative, and atypical bacteria. by Huband MD, Bradford PA, Otterson LG, Basarab GS, Kutschke AC, Giacobbe RA, Patey SA, Alm RA, Johnstone MR, Potter ME, Miller PF and Mueller JP published in Antimicrob. Agents Chemother. 2015; 59 (1): 467-474

Ceftaroline: clinical and microbiology experience with focus on methicillin-resistant Staphylococcus aureus after regulatory approval in the USA.

Ceftaroline: clinical and microbiology experience with focus on methicillin-resistant Staphylococcus aureus after regulatory approval in the USA. by Stryjewski ME, Jones RN and Corey GR published in Diagn. Microbiol. Infect. Dis. 2015; 81 (3): 183-188

Antimicrobial activity of ceftaroline tested against bacterial isolates causing respiratory tract and skin and skin structure infections in US medical centers in 2013.

Antimicrobial activity of ceftaroline tested against bacterial isolates causing respiratory tract and skin and skin structure infections in US medical centers in 2013. by Sader HS, Farrell DJ, Mendes RE, Flamm RK, Castanheira M and Jones RN published in Diagn. Microbiol. Infect. Dis. 2015; 82 (1): 78-84

Antimicrobial activity of solithromycin against serotyped macrolide-resistant Streptococcus pneumoniae isolates collected from U.S. medical centers in 2012.

Antimicrobial activity of solithromycin against serotyped macrolide-resistant Streptococcus pneumoniae isolates collected from U.S. medical centers in 2012. by Farrell DJ, Mendes RE and Jones RN published in Antimicrob. Agents Chemother. 2015; 59 (4): 2432-2434

Isavuconazole, micafungin, and 8 comparator antifungal agents’ susceptibility profiles for common and uncommon opportunistic fungi collected in 2013: Temporal analysis of antifungal drug resistance using CLSI species-specific clinical breakpoints and proposed epidemiological cutoff values.

Isavuconazole, micafungin, and 8 comparator antifungal agents’ susceptibility profiles for common and uncommon opportunistic fungi collected in 2013: Temporal analysis of antifungal drug resistance using CLSI species-specific clinical breakpoints and proposed epidemiological cutoff values. by Pfaller MA, Rhomberg PR, Messer SA, Jones RN and Castanheira M published in Diagn. Microbiol. Infect. Dis. 2015; 82 (4): 303-313

In vitro activity of a Hos2 deacetylase inhibitor, MGCD290, in combination with echinocandins against echinocandin-resistant Candida species.

In vitro activity of a Hos2 deacetylase inhibitor, MGCD290, in combination with echinocandins against echinocandin-resistant Candida species. by Pfaller MA, Rhomberg PR, Messer SA and Castanheira M published in Diagn. Microbiol. Infect. Dis. 2015; 81 (4): 259-263

Ceftaroline activity against bacterial pathogens frequently isolated in U.S. medical centers: results from five years of the AWARE surveillance program.

Ceftaroline activity against bacterial pathogens frequently isolated in U.S. medical centers: results from five years of the AWARE surveillance program. by Sader HS, Flamm RK, Streit J, Farrell DJ and Jones RN published in Antimicrob. Agents Chemother. 2015; 59 (4): 2458-2461,

Surrogate analysis of vancomycin to predict susceptible categorization of dalbavancin.

Surrogate analysis of vancomycin to predict susceptible categorization of dalbavancin. by Jones RN, Farrell DJ, Flamm RK, Sader HS, Dunne MW and Mendes RE published in Diagn. Microbiol. Infect. Dis. 2015; 82 (1): 73-77

Use of in vitro vancomycin testing results to predict susceptibility to oritavancin, a new long-acting lipoglycopeptide.

Use of in vitro vancomycin testing results to predict susceptibility to oritavancin, a new long-acting lipoglycopeptide. by Jones RN, Turnidge JD, Moeck G, Arhin FF and Mendes RE published in Antimicrob. Agents Chemother. 2015; 59 (4): 2405-2409,

Update of the telavancin activity in vitro tested against a worldwide collection of Gram-positive clinical isolates (2013), when applying the revised susceptibility testing method.

Update of the telavancin activity in vitro tested against a worldwide collection of Gram-positive clinical isolates (2013), when applying the revised susceptibility testing method. by Mendes RE, Farrell DJ, Sader HS, Streit JM and Jones RN published in Diagn. Microbiol. Infect. Dis. 2015; 81 (4): 275-279

MSSA ST398/t034 carrying a plasmid-mediated cfr and erm(B) in Brazil.

MSSA ST398/t034 carrying a plasmid-mediated cfr and erm(B) in Brazil. by Gales AC, Deshpande LM, de Souza AG, Pignatari AC and Mendes RE published in J. Antimicrob. Chemother. 2015; 70 (1): 303-305

In vitro activity of linezolid as assessed through the 2013 LEADER surveillance program.

In vitro activity of linezolid as assessed through the 2013 LEADER surveillance program. by Flamm RK, Mendes RE, Hogan PA, Ross JE, Farrell DJ and Jones RN published in Diagn. Microbiol. Infect. Dis. 2015; 81 (4): 283-289

Activity of Debio1452, a FabI inhibitor with potent activity against S. aureus and coagulase-negative Staphylococcus spp., including multidrug-resistant strains.

Activity of Debio1452, a FabI inhibitor with potent activity against S. aureus and coagulase-negative Staphylococcus spp., including multidrug-resistant strains. by Flamm RK, Rhomberg P, Kaplan N, Jones RN and Farrell DJ published in Antimicrob. Agents Chemother. 2015; 59 (5): 2583-2587

In vitro antibacterial activity of AZD0914 against human mycoplasmas and ureaplasmas.

In vitro antibacterial activity of AZD0914 against human mycoplasmas and ureaplasmas. by Waites KB, Crabb DM, Duffy LB and Huband MD published in Antimicrob. Agents. Chemother. 2015; 59 (6): 3627-3629

Cytotoxic virulence predicts mortality in nosocomial pneumonia due to methicillin-resistant Staphylococcus aureus.

Cytotoxic virulence predicts mortality in nosocomial pneumonia due to methicillin-resistant Staphylococcus aureus. by Rose HR, Holzman RS, Altman DR, Smyth DS, Wasserman GA, Kafer JM, Wible M, Mendes RE, Torres VJ and Shopsin B published in J. Infect. Dis. 2015; 211 (12): 1862-1874

Ceftazidime-avibactam activity tested against Enterobacteriaceae from United States hospitals (2011-2013) and characterization of beta-lactamase producing strains.

Ceftazidime-avibactam activity tested against Enterobacteriaceae from United States hospitals (2011-2013) and characterization of beta-lactamase producing strains. by Castanheira M, Mills JC, Costello SE, Jones RN and Sader HS published in Antimicrob. Agents Chemother. 2015; 59 (6): 3509-3517

Differences in Potency and Categorical Agreement between COL and Poly B against 15,377 Strains Collected WW

Differences in Potency and Categorical Agreement between COL and Poly B against 15,377 Strains Collected WW, Lead author: Sader HS, presented at ID Week, October 8 – 12, 2014, Philadelphia, PA